Instrument Inactif

Autres langues Carbylan Therapeutics Inc Nasdaq

Actions

US1413841073

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

KalVista Pharmaceuticals Presents Data at Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024	06/06
KalVista Pharmaceuticals, Inc. Presents Data At Eastern Allergy Conference 2024 and the Japanese Dermatological Association 2024	06/06
KalVista Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	05/06
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	04/06
KalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024	03/06
Kalvista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema At the European Academy of Allergy and Clinical Immunology Congress 2024	03/06
Sector Update: Health Care Stocks Higher Late Afternoon	31/05
Sector Update: Health Care	31/05
KalVista Prospective Treatment for Swelling Disorder Meets Objectives -- Shares Rise	31/05
Kalvista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating Its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema	31/05
KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema	31/05
KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024	24/05
Kalvista Pharmaceuticals Insider Sold Shares Worth $258,337, According to a Recent SEC Filing	22/05
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences	21/05
KalVista Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	03/05
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	02/05
KalVista Pharmaceuticals : Corporate Presentation May 2024	02/05
KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year	01/05
KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors	22/04
Kalvista Pharmaceuticals, Inc. Appoints William C. Fairey to the Board of Directors	22/04

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Carbylan Therapeutics Inc Nasdaq

Actions

US1413841073

Autres langues

Filtres